1-(5-(1H-1,2,4-Triazol-5-Yl)(1H-Indazol-3-Yl))-3-(2-Piperidylethoxy) Benzene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(5-(1H-1,2,4-Triazol-5-Yl)(1H-Indazol-3-Yl))-3-(2-Piperidylethoxy) Benzene
• 英文别名: 1-(5-(1H-1,2,4-Triazol-5-YL)(1H-indazol-3-YL))-3-(2-piperidylethoxy)benzene；3-[3-(2-piperidin-2-ylethoxy)phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole
• 化学式: C₂₂H₂₄N₆O
• 分子量: 388.472
• InChiKey: AKOJYTCILKJACP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  91.5
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-羟乙基哌啶 、 3-{1-Perhydro-2H-Pyran-2-Yl-5-[1-(Triphenylmethyl)(1,2,4-Triazol-3-Yl)]-1H-Indazol-3-Yl]Phenol 、 偶氮二甲酸二乙酯 在 sodium hydroxide 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 为溶剂， 以48%的产率得到1-(5-(1H-1,2,4-Triazol-5-Yl)(1H-Indazol-3-Yl))-3-(2-Piperidylethoxy) Benzene
  参考文献：
  名称：

  Methods for treating an inflammatory condition or inhibiting JNK

  摘要：

  这项发明通常涉及吲唑衍生物，具有以下结构： 1 或药用可接受的盐，其中R 1 ，R 2 和A如本文所述定义。这类化合物在治疗对JNK抑制剂有响应的广泛疾病和障碍，如炎症性疾病或障碍中具有用途。因此，还披露了治疗这些疾病和障碍的方法，以及包含一个或多个上述化合物的药物组合物。

  公开号：

  US20040127536A1

文献信息

• Indazole compounds, compositions thereof and methods of treatment therewith
  申请人：Bhagwat S. Shripad

  公开号：US20050009876A1

  公开（公告）日：2005-01-13

  This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

  这项发明通常涉及使用吲唑化合物来治疗或预防与蛋白激酶相关的疾病，包括酪氨酸激酶，诸如增殖性疾病、炎症性疾病、异常血管生成及其相关疾病、动脉硬化、黄斑变性、糖尿病、肥胖、疼痛等。这些方法包括向有需要的患者施用有效量的吲唑化合物，以抑制、调节或控制酪氨酸激酶信号转导。本文中提供了一种新型的吲唑化合物或其药用可接受的盐。
• Indazole derivatives as JNK inhibitors and compositions and methods related thereto
  申请人：——

  公开号：US20020103229A1

  公开（公告）日：2002-08-01

  Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: 1 wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  本发明公开了作为JNK选择性抑制剂的化合物。本发明的化合物是吲唑衍生物，具有以下结构： 1 其中R 1 ，R 2 和A如本文所述定义。此类化合物在治疗对JNK抑制产生响应的广泛病症方面具有用途。因此，还公开了治疗此类病症的方法，以及包含一个或多个上述化合物的药物组合物。
• Solid forms of a JNK inhibitor
  申请人：Saindane Manohar

  公开号：US20060258706A1

  公开（公告）日：2006-11-16

  The present invention provides solid forms of Compound (I), pharmaceutical compositions thereof, and methods for the treatment or prevention of diseases including, but not limited to a liver disease, cancer, a cardiovascular disease, a metabolic disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension, ischemia/reperfusion injury, central nervous system (CNS) injury/damage or a disease treatable or preventable by the inhibition of JNK. In particular, the invention relates to certain novel crystal forms of the compound 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene.

  本发明提供了化合物(I)的固体形式，以及其药物组合物和用于治疗或预防疾病的方法，包括但不限于肝病、癌症、心血管疾病、代谢性疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、疼痛及相关综合征、与疾病相关的消耗、石棉相关疾病、肺动脉高压、缺血/再灌注损伤、中枢神经系统（CNS）损伤/损害或通过抑制JNK可治疗或预防的疾病。具体而言，本发明涉及化合物1-(5-(1H-1,2,4-三唑-5-基)(1H-吲哚-3-基))-3-(2-哌啶基乙氧基)苯的某些新型晶体形式。
• Methods for treating or preventing acute myelogenous leukemia
  申请人：Bhagwat S. Shripad

  公开号：US20070004777A1

  公开（公告）日：2007-01-04

  This invention is generally directed to methods for treating or preventing acute myelogenous leukemia (“AML”) comprising administering to a patient in need thereof an effective amount of an Indazole Compound having the structure: or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer or enantiomer thereof, wherein R 1 , R 2 and A are as defined herein.

  本发明通常涉及用于治疗或预防急性髓性白血病（“AML”）的方法，包括向需要治疗的患者施用具有以下结构的Indazole化合物的有效量：或其药学上可接受的盐，溶剂化合物，水合物，前药，立体异构体或对映体，其中R1，R2和A如此处所定义。
• Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
  申请人：Signal Pharmaceuticals, LLC

  公开号：US07208513B2

  公开（公告）日：2007-04-24

  Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  本发明揭示了具有选择性抑制JNK活性的化合物。本发明的化合物是具有以下结构的吲唑衍生物：其中R1、R2和A的定义如本文所述。这些化合物在治疗对JNK抑制有反应的广泛疾病方面具有用途。因此，本发明还揭示了治疗这些疾病的方法，以及包含上述化合物中的一个或多个化合物的制药组合物。